Avoid common mistakes on your manuscript.
While meningiomas are generally benign, slow-growing tumors with excellent post-surgical outcomes, a significant subset follows a more aggressive clinical course resistant to existing treatment modalities. Recent genomic profiling studies have led to refined classification schemes that better predict patient outcomes compared to conventional morphologic assessment alone [1, 2, 8]. We now recognize that patients with meningiomas harboring CDKN2A homozygous deletion or TERT promoter mutation regardless of histologic grade have poor clinical outcomes similar to patients with histologically diagnosed anaplastic (CNS WHO grade 3) meningiomas [10]. As such, the revised definition of anaplastic meningioma in the 2021 WHO Classification of Central Nervous System Tumors now includes any meningioma that harbors TERT promoter mutation or CDKN2A homozygous deletion [6]. However, there are no uniform recommendations on a standardized molecular workup for meningioma, and the cost of ancillary sequencing remains prohibitive at most institutions. Prior studies have examined p16 expression in meningioma but not in the context of corresponding CDKN2A gene status [3, 5]. An unresolved question is whether loss of expression of p16INK4a (the protein product of the CDKN2A gene which functions as a negative regulator of cyclin-dependent kinase activity—hereafter p16) by immunohistochemistry can identify likely CDKN2A-inactivated meningiomas to be selectively confirmed by follow-up molecular testing.
To explore this, we assembled a cohort of 39 higher grade meningiomas with CDKN2A gene status determined by targeted next-generation DNA sequencing (Fig. 1, Supplementary Table 1 [Online Resource 1]). The cohort was composed of 21 males and 18 females, with a mean age at surgery of 57 years (range 16 to 89 years). Tumors were located in the convexity (19), skull base (10), falx/parasagittal (6), spinal cord (3), and metastatic to pelvic bones (1). 24 were initial primary tumors, 14 were recurrent tumors, and 1 was a metastasis. By contemporary morphologic grading criteria, all were histologically higher-grade, either atypical (grade 2, n = 27, 69%) or anaplastic (grade 3, n = 12, 31%). Targeted capture-based next-generation DNA sequencing was performed using the UCSF500 NGS panel as previously described [4]. Genome-wide copy number and zygosity analysis was performed by CNVkit and visualized using NxClinical (Biodiscovery). Manual review of chromosome 9 and the CDKN2A locus was performed in all tumors. An integrated molecular grade based on TERT promoter and CDKN2A status was assigned for each tumor per the 2021 WHO Classification. Immunohistochemistry for p16 was performed on whole formalin-fixed paraffin-embedded sections for all 39 tumors as described in Methods.
By targeted DNA sequencing, seven tumors demonstrated focal CDKN2A homozygous/biallelic deletion. These seven meningiomas harboring CDKN2A homozygous deletion demonstrated complete absence of p16 expression by immunohistochemistry, with intact staining in non-neoplastic endothelial and inflammatory cells (Fig. 1, Supplementary Fig. 1 [Online Resource 2]). An additional meningioma (case #43) harbored an inactivating truncating mutation in CDKN2A (p.A60fs) with loss of the remaining wildtype allele which also demonstrated complete absence of p16 expression (Supplementary Fig. 1 [Online Resource 2]). Three meningiomas (cases #5, #6, and #7, all morphologically grade 2) with no identifiable CDKN2A alteration had absence of p16 immunoreactivity. The remaining 28 meningiomas with no identifiable CDKN2A alteration demonstrated intact p16 expression with immunoreactivity present in a substantial proportion of tumor cells (Fig. 1). These findings translated to an overall sensitivity of 100% (8/8) for p16 loss by immunohistochemistry in detecting CDKN2A biallelic inactivation among higher grade meningiomas, a specificity of 90% (28/31), a negative predictive value of 100% (28/28), and a positive predictive value of 73% (8/11).
We also performed p16 immunohistochemistry on 14 CNS WHO grade 1 meningiomas that were all confirmed by DNA sequencing to have intact/wildtype CDKN2A alleles (Supplementary Table 2 [Online Resource 1]). The majority of these CNS WHO grade 1 meningiomas (9/14, 64%) demonstrated minimal to absent p16 immunoreactivity (Supplementary Fig. 2 [Online Resource 2]), indicating a poor correlation between p16 expression and CDKN2A gene status in benign CNS WHO grade 1 meningiomas which we speculate is due to the low proliferation rate and cell cycle activity. As a result, we do not foresee that p16 immunohistochemistry is an effective screening tool for CDKN2A inactivation in CNS WHO grade 1 meningiomas and only recommend p16 immunohistochemical evaluation in higher grade meningiomas.
For morphologically grade 2 meningiomas, identification of an underlying CDKN2A homozygous deletion would now lead to an integrated CNS WHO grade 3 designation that has treatment implications including clinical trial eligibility. Among 27 morphologically grade 2 meningiomas in our cohort, four demonstrated loss of p16 expression. Of these four, one was confirmed to harbor CDKN2A homozygous deletion and was subsequently increased to CNS WHO grade 3, while the other three had intact/wildtype CDKN2A alleles. The remaining 23 histologically grade 2 tumors showed retained p16 expression and intact/wildtype CDKN2A alleles. In a resource-limited setting, screening morphologically grade 2 meningiomas with p16 immunohistochemistry can help identify a subset of cases to submit for additional CDKN2A assessment and possible change in grade.
For morphologic grade 3 tumors, CDKN2A homozygous deletion does not affect grading but may have treatment implications. CDKN2A encodes a cell cycle regulatory protein, and ongoing clinical trials are examining the role of CDK4/6 inhibition in meningioma [12]. Among 12 histologically grade 3 tumors, seven demonstrated loss of p16 expression, of which six harbored CDKN2A homozygous deletion and one harbored a truncating mutation in CDKN2A (p.A60fs). Notably, CDKN2A truncating mutations are not currently included in the molecular criteria for CNS WHO grade 3 designation but are likely functionally equivalent to homozygous deletion. Thus, morphologically grade 3 meningiomas demonstrating loss of p16 expression may be considered for further investigation as part of ongoing trials using cell cycle inhibitors such as ribociclib (NCT02933736) and abemaciclib (NCT02523014, NCT03220646). Additionally, cases with intratumoral heterogeneity may only harbor biallelic inactivation of CDKN2A in a subset of tumor cells [7, 9, 11]. In such cases, p16 immunohistochemistry may help identify the region of tumor with CDKN2A inactivation that should be targeted for microdissection and ancillary confirmatory studies.
In summary, we demonstrate meningiomas harboring CDKN2A homozygous deletion or truncating mutation exhibit loss of p16 expression by immunohistochemistry. As such, these results suggest that p16 immunohistochemistry can act as a cost- and time-effective prospective screen of CDKN2A gene status in the context of histologically higher grade meningiomas, with loss of p16 expression prompting additional molecular testing to confirm CDKN2A mutation or deletion. Future studies are required to define the biologic nature of the subset of meningiomas with loss of p16 expression by immunohistochemistry but an absence of identifiable CDKN2A gene alterations.
Methods for p16 immunohistochemistry
Immunohistochemistry for p16INK4a was performed on whole formalin-fixed paraffin-embedded sections in a Leica Bond autostainer using the mouse monoclonal antibody clone E6H4 from Roche MTM Laboratories following ER1 antigen retrieval. The primary antibody was applied for 30 min at room temperature undiluted at ready-to-use concentration as supplied by the manufacturer. Diaminobenzidine was used as the chromogen, followed by hematoxylin counterstain.
Data availability
Digitally scanned image files of representative H&E and p16 immunostained sections are available at the following link: https://figshare.com/projects/Meningiomas_with_and_without_CDKN2A_homozygous_deletion/155759. Detailed clinicopathologic annotations are available in the electronic supplementary material. Raw sequencing data files are available upon request.
References
Choudhury A, Magill ST, Eaton CD et al (2022) Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Nat Genet 54(5):649–659. https://doi.org/10.1038/s41588-022-01061-8
Driver J, Hoffman SE, Tavakol S et al (2022) A molecularly integrated grade for meningioma. Neuro Oncol 24(5):796–808. https://doi.org/10.1093/neuonc/noab213
Kim MS, Kim KH, Lee EH et al (2014) Results of immunohistochemical staining for cell cycle regulators predict the recurrence of atypical meningiomas. J Neurosurg 121(5):1189–1200. https://doi.org/10.3171/2014.7.JNS132661
Kline CN, Joseph NM, Grenert JP et al (2017) Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro Oncol 19(5):699–709. https://doi.org/10.1093/neuonc/now254
Korshunov A, Shishkina L, Golanov A (2003) Immunohistochemical analysis of p16INK4a, p14ARF, p18INK4c, p21CIP1, p27KIP1 and p73 expression in 271 meningiomas correlation with tumor grade and clinical outcome. Int J Cancer 104(6):728–734. https://doi.org/10.1002/ijc.11013
Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23(8):1231–1251. https://doi.org/10.1093/neuonc/noab106
Magill ST, Vasudevan HN, Seo K et al (2020) Multiplatform genomic profiling and magnetic resonance imaging identify mechanisms underlying intratumor heterogeneity in meningioma. Nat Commun 11(1):4803. https://doi.org/10.1007/s00401-022-02455-y
Paramasivam N, Hübschmann D, Toprak UH et al (2019) Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. Acta Neuropathol 138(2):295–308. https://doi.org/10.1007/s00401-019-02008-w
Sasaki S, Takeda M, Hirose T et al (2022) Correlation of MTAP immunohistochemistry with cdkn2a status assessed by fluorescence in situ hybridization and clinicopathological features in cns who grade 2 and 3 meningiomas: a single center cohort study. J Neuropathol Exp Neurol 81(2):117–126. https://doi.org/10.1093/jnen/nlab127
Sievers P, Hielscher T, Schrimpf D et al (2020) CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol 140(3):409–413. https://doi.org/10.1007/s00401-020-02188-w
Vasudevan HN, Choudhury A, Hilz S et al (2022) Intratumor and informatic heterogeneity influence meningioma molecular classification. Acta Neuropathol. https://doi.org/10.1007/s00401-022-02455-y
Young JS, Kidwell RL, Zheng A et al (2022) CDK 4/6 inhibitors for the treatment of meningioma. Front Oncol 12:93137. https://doi.org/10.3389/fonc.2022.931371
Acknowledgements
D.A.S. was supported by the Morgan Adams Foundation, the Yuvaan Tiwari Foundation, and the NIH Director’s Early Independence Award from the Office of the Director, NIH (DP5 OD021403). C.G.L. was supported by the UCSF Training Program in Translational Brain Tumor Research, National Cancer Institute, NIH (T32 CA151022). We thank the staff of the UCSF Clinical Cancer Genomics Laboratory for assistance with genetic profiling.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
A.P. and D.A.S. are members of the editorial board for Acta Neuropathologica. They were not involved in the assessment or decision-making process for this manuscript. The other authors declare that they have no competing interests related to this report.
Ethical approval
This study was approved by the Committee on Human Research of the University of California, San Francisco, with a waiver of patient consent.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Tang, V., Lu, R., Mirchia, K. et al. Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas. Acta Neuropathol 145, 497–500 (2023). https://doi.org/10.1007/s00401-023-02544-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00401-023-02544-6